We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
-2.71%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$55.4M
AUM Growth
+$2.06M
Cap. Flow
+$13.9M
Cap. Flow %
25.13%
Top 10 Hldgs %
80.61%
Holding
29
New
10
Increased
2
Reduced
3
Closed
7

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$3.43M
2
CVS icon
CVS Health
CVS
+$2.96M
3
WBA
Walgreens Boots Alliance
WBA
+$2.68M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$2.02M
5
COR icon
Cencora
COR
+$1.72M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$2.17M
2
GSK icon
GSK
GSK
+$823K
3
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$290K

Sector Composition

Rank Sector Weight
1 Healthcare 57.5%
2 Miscellaneous 41.28%
3 Consumer Staples 1.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$827B
$14.8M 26.8%
50,000
+30,000
+150% +$8.86M
GILD icon
2
Gilead Sciences
GILD
$185B
$4.44M 8.01%
70,000
– –
GSK icon
3
GSK
GSK
$101B
$4.27M 7.71%
80,000
-16,000
-17% -$823K
VIXY icon
4
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$212M
$3.9M 7.05%
2,500
+2,187
+699% +$3.58M
ABBV icon
5
AbbVie
ABBV
$456B
$3.79M 6.84%
+50,000
New +$3.43M
GILD icon
6
CALL
Gilead Sciences
GILD
$185B
$3.17M 5.72%
50,000
-100,000
-67% -$6.54M
CVS icon
7
CVS Health
CVS
$119B
$3.15M 5.7%
+50,000
New +$2.96M
WBA
8
DELISTED
Walgreens Boots Alliance
WBA
$2.77M 5%
+50,000
New +$2.68M
TYME
9
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$2.59M 4.67%
2,175,000
– –
VKTX icon
10
Viking Therapeutics
VKTX
$3.95B
$1.72M 3.11%
250,000
– –
CAH icon
11
Cardinal Health
CAH
$54.7B
$1.65M 2.98%
+35,000
New +$1.6M
COR icon
12
Cencora
COR
$61.3B
$1.65M 2.97%
+20,000
New +$1.72M
MCK icon
13
McKesson
MCK
$104B
$1.37M 2.47%
+10,000
New +$1.42M
ADMS
14
DELISTED
Adamas Pharmaceuticals
ADMS
$1.02M 1.85%
200,000
– –
NVLN
15
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$1.01M 1.83%
1,400,000
-400,000
-22% -$290K
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
$983K 1.78%
+250,000
New +$2.02M
FOMX
17
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$760K 1.37%
+250,000
New +$703K
GNLN icon
18
Greenlane Holdings
GNLN
$1.95M
– –
0
– –
ATRS
19
CALL
DELISTED
Antares Pharma, Inc.
ATRS
$669K 1.21%
200,000
– –
ATRS
20
DELISTED
Antares Pharma, Inc.
ATRS
$669K 1.21%
+200,000
New +$659K
FOMX
21
CALL
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$152K 0.27%
+50,000
New +$141K
TYME
22
CALL
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$119K 0.21%
100,000
– –
ABBV icon
23
CALL
AbbVie
ABBV
$456B
– –
-50,000
Closed -$3.64M
CRON
24
PUT
Cronos Group
CRON
$1.25B
– –
-50,000
Closed -$799K
CVS icon
25
CALL
CVS Health
CVS
$119B
– –
-50,000
Closed -$2.73M
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Healthcare Value Capital held 29 positions worth $55.4M, up 3.9% from $53.3M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Healthcare Value Capital deployed $13.9M of net new capital in Q3 2019, opening 10 new positions and adding to 2 existing holdings. Its largest new stake was AbbVie: 50,000 shares worth $3.79M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 36% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was GSK, an estimated $823K trimmed.

  • Healthcare Value Capital's largest Q3 2019 buy was AbbVie: 50,000 shares worth $3.79M.
  • Healthcare Value Capital's biggest Q3 2019 reduction was GSK, cutting an estimated $823K.
  • Healthcare Value Capital fully exited Pfizer in Q3 2019, selling an estimated $2.17M.
  • Healthcare Value Capital's ten largest holdings make up 81% of its $55.4M portfolio in Q3 2019.
  • Healthcare Value Capital opened 10 new positions and closed 7 in Q3 2019.
  • Healthcare Value Capital's portfolio value rose 3.9% quarter-over-quarter to $55.4M.

Based on Healthcare Value Capital's 13F filing for Q3 2019, filed 14 Nov 2019.